MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

Search

Catalyst Pharmaceuticals Inc

Open

BrancheGesundheitswesen

21.11 0.86

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

20.67

Max

21.27

Schlüsselkennzahlen

By Trading Economics

Einkommen

801K

57M

Verkäufe

-399K

141M

KGV

Branchendurchschnitt

13.771

39.857

Gewinnspanne

40.119

Angestellte

181

EBITDA

526K

73M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+54.16% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-369M

2.7B

Vorheriger Eröffnungskurs

20.25

Vorheriger Schlusskurs

21.11

Nachrichtenstimmung

By Acuity

26%

74%

56 / 376 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Catalyst Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

15. Juli 2025, 23:41 UTC

Market Talk

Nikkei May Trade in Range Amid Tariff Uncertainty -- Market Talk

15. Juli 2025, 23:40 UTC

Market Talk

Gold Edges Higher on Possible Position Adjustments -- Market Talk

15. Juli 2025, 23:05 UTC

Market Talk

Auckland International Airport Passenger Growth May Disappoint Again -- Market Talk

15. Juli 2025, 21:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. Juli 2025, 21:36 UTC

Market Talk

Canada CPI Data Fuel Rate-Prediction Revisions -- Market Talk

15. Juli 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

15. Juli 2025, 20:50 UTC

Market Talk
Ergebnisse

Financial Services Roundup: Market Talk

15. Juli 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. Juli 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

15. Juli 2025, 20:14 UTC

Akquisitionen, Fusionen, Übernahmen

Chinese EV Makers to Combine. Geely Is Buying Zeekr. -- Barrons.com

15. Juli 2025, 20:07 UTC

Ergebnisse

BlackRock Shares Tumble After Big Client Redemption Blunts Quarterly Results -- Update

15. Juli 2025, 20:06 UTC

Market Talk

Nvidia, AMD Seen Benefiting from Return to Chinese Chip Sales -- Market Talk

15. Juli 2025, 19:54 UTC

Market Talk

Global Equities Roundup: Market Talk

15. Juli 2025, 19:54 UTC

Market Talk

Meta CEO Hints at Higher Revenues, Expenses With Data Center Plans -- Market Talk

15. Juli 2025, 19:38 UTC

Market Talk

Oil Falls As Eventual Oversupply Concerns Weigh -- Market Talk

15. Juli 2025, 19:09 UTC

Market Talk

U.S. Natural Gas Futures Post Back-to-Back Gains -- Market Talk

15. Juli 2025, 19:07 UTC

Market Talk

Canada CFOs Willing to Take Risks, Increase Spending -- Market Talk

15. Juli 2025, 19:03 UTC

Market Talk

Gold Slips as Big Buyers Pull Back -- Market Talk

15. Juli 2025, 18:32 UTC

Akquisitionen, Fusionen, Übernahmen

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

15. Juli 2025, 18:31 UTC

Akquisitionen, Fusionen, Übernahmen

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

15. Juli 2025, 18:13 UTC

Market Talk

Canada Adopts 'Note of Realism' in US Trade Talks, Setting Stage for Possible Tariff Deal -- Market Talk

15. Juli 2025, 17:40 UTC

Market Talk

Canadian Inflation Adds to Case for Bank of Canada Extending Pause -- Market Talk

15. Juli 2025, 17:40 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. Juli 2025, 17:25 UTC

Akquisitionen, Fusionen, Übernahmen

National Fuel Gas Gets Rare Double Upgrade. Buy the Stock, Analyst Says. -- Barrons.com

15. Juli 2025, 17:24 UTC

Market Talk

Dollar Gains Strength After Inflation Data -- Market Talk

15. Juli 2025, 16:49 UTC

Market Talk

Oil Futures Likely to Continue Sideways Trade -- Market Talk

15. Juli 2025, 16:20 UTC

Market Talk
Ergebnisse

Financial Services Roundup: Market Talk

15. Juli 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. Juli 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

15. Juli 2025, 15:42 UTC

Market Talk

Coca-Cola Seen as Top Pick Ahead of Consumer Staples Earnings -- Market Talk

Peer-Vergleich

Kursveränderung

Catalyst Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

54.16% Vorteil

12-Monats-Prognose

Durchschnitt 33.33 USD  54.16%

Hoch 35 USD

Tief 31 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Catalyst Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

4

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

N/A / 24.28Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

56 / 376 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.